Christine Fritsch
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Biochemical and Molecular Research, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity(2008)1,147 cited
- → Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor(2011)525 cited
- → Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials(2014)491 cited
- → Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation(2013)463 cited
- → Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma(2013)328 cited
- → Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells(2009)318 cited